Urothelial ESMO 2025 Updates
Two Onc Docs
00:00
IMvigor011: ctDNA-guided adjuvant atezolizumab
Kareen explains the ctDNA risk-adapted IMvigor011 results, showing DFS and OS benefit in ctDNA-positive patients and implications for personalized care.
Play episode from 05:55
Transcript
